PRNewsWire
13 Jul 2026, 09:30 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
PharmatrophiX's lead candidate LM11A-31 demonstrated a statistically significant, dose-dependent slowing of decline in brain network function compared to placebo in a Phase 2a trial for Alzheimer's. — Positive Phase 2a results for a disease-modifying Alzheimer's drug significantly increase the probability of clinical success and company valuation.
+0.60The analysis of 159 participants showed the strongest positive effects on metabolic connectivity and network efficiency in the higher 400 mg dose group. — Establishment of a dose-response relationship is a critical regulatory requirement for advancing to Phase 3 trials.
+0.40The study utilized a novel metabolic brain functional-network connectivity mapping technology from Indiana University to quantify brain communication networks. — While technologically significant, the use of a new imaging tool is a supporting detail rather than a primary driver of asset value.
+0.20Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
8h ago
